Evidence-based medicine has been hijacked: a report to David Sackett.

[1]  S. Ebrahim,et al.  Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. , 2016, Journal of clinical epidemiology.

[2]  John P A Ioannidis,et al.  Evaluation of Wellness Determinants and Interventions by Citizen Scientists. , 2015, JAMA.

[3]  A. Baccarelli,et al.  IARC Monographs: 40 Years of Evaluating Carcinogenic Hazards to Humans , 2015, Environmental health perspectives.

[4]  Fiona Godlee,et al.  Too much medicine , 2013, BMJ : British Medical Journal.

[5]  Monique L. Anderson,et al.  Compliance with results reporting at ClinicalTrials.gov. , 2015, The New England journal of medicine.

[6]  Petroc Sumner,et al.  The association between exaggeration in health related science news and academic press releases: retrospective observational study , 2014, BMJ : British Medical Journal.

[7]  Jeremy Howick,et al.  How evidence-based medicine is failing due to biased trials and selective publication. , 2014, Journal of evaluation in clinical practice.

[8]  T. Greenhalgh,et al.  Evidence based medicine: a movement in crisis? , 2014, BMJ : British Medical Journal.

[9]  Published Online.  Biomedical research: increasing value, reducing waste , 2014 .

[10]  John P A Ioannidis,et al.  Ensuring the integrity of clinical practice guidelines: a tool for protecting patients , 2013, BMJ : British Medical Journal.

[11]  F. Godlee,et al.  Too much medicine; too little care , 2013, BMJ.

[12]  J. Ioannidis,et al.  Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. , 2013, Journal of clinical epidemiology.

[13]  J. Ioannidis.  Mega-trials for blockbusters. , 2013, JAMA.

[14]  Karina D. Torralba,et al.  Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[15]  D. Sackett,et al.  Clinician-trialist rounds: 10. Mentoring – part 4: attributes of an effective mentor , 2012, Clinical trials.

[16]  Trisha Greenhalgh,et al.  Why do we always end up here? Evidence-based medicine's conceptual cul-de-sacs and some off-road alternative routes. , 2012, Journal of primary health care.

[17]  John P A Ioannidis,et al.  Research needs grants, funding and money – missing something? , 2012, European journal of clinical investigation.

[18]  D. Sackett,et al.  Clinician-trialist rounds: 9. Mentoring – part 3: the structure and function of effective mentoring: advice and protection , 2012, Clinical trials.

[19]  John P A Ioannidis,et al.  Are medical conferences useful? And for whom? , 2012, JAMA.

[20]  D. Contopoulos-Ioannidis,et al.  Claims for improved survival from systemic corticosteroids in diverse conditions: an umbrella review , 2012, European journal of clinical investigation.

[21]  Sharon E Straus,et al.  Clinician-trialist rounds: 8. Mentoring – part 2: the structure and function of effective mentoring linkage, resources, and academic opportunities , 2012, Clinical trials.

[22]  D. Sackett,et al.  Clinician-trialist rounds: 7. Mentoring: why every clinician-trialist needs to get mentored , 2011, Clinical trials.

[23]  Deborah Grady,et al.  Less is more: how less health care can result in better health. , 2010, Archives of internal medicine.

[24]  Paolo Boffetta,et al.  False-Positive Results in Cancer Epidemiology: A Plea for Epistemological Modesty , 2008, Journal of the National Cancer Institute.

[25]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[26]  Charles Anderson,et al.  The end of theory: The data deluge makes the scientific method obsolete , 2008 .

[27]  Douglas G Altman,et al.  Ghost Authorship in Industry-Initiated Randomised Trials , 2007, PLoS medicine.

[28]  Peter C Gøtzsche,et al.  Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review , 2006, BMJ : British Medical Journal.

[29]  David Michaels,et al.  Doubt is their product. , 2005, Scientific American.

[30]  D. Wilkinson.  ICRAM (the International Campaign to Revitalise Academic Medicine): agenda setting , 2004, BMJ : British Medical Journal.

[31]  D. Sackett.  Campaign to revitalise academic medicine: Don't believe us , 2004, British medical journal.

[32]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[33]  D. Sackett.  Clinical epidemiology. what, who, and whither. , 2002, Journal of clinical epidemiology.

[34]  J. Ioannidis,et al.  Arabian nights—1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report , 2000, BMJ : British Medical Journal.

[35]  David L Sackett,et al.  The sins of expertness and a proposal for redemption , 2000, BMJ : British Medical Journal.

[36]  J. Grimshaw,et al.  Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.

[37]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[38]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: I. How to Get Started , 1993 .

[39]  G H Guyatt,et al.  Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. , 1993, JAMA.

[40]  A. Detsky,et al.  Evidence-based medicine. A new approach to teaching the practice of medicine. , 1992, JAMA.

[41]  D. Sackett.  Second thoughts. Proposals for the health sciences--I. Compulsory retirement for experts. , 1983, Journal of chronic diseases.